Inventor · disambiguated record
Knut Eis
Also filed as: EIS KNUT
35 granted patents·27 pending applications·190 citations·filing 2003–2024
96Inventor score
Top patents by PatentIndex Score
62 records- 0196US9549932B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2016·Granted Jan 24, 2017·26 cites·30 claims
- 0294US9284319B2Heterocyclyl aminoimidazopyridazinesEIS KNUT·Filed 2012·Granted Mar 15, 2016·28 cites·5 claims
- 0393US11492358B1Macrocyclic indole derivativesBAYER AG·Filed 2021·Granted Nov 8, 2022·3 cites·18 claims
- 0492US10981932B2Macrocyclic indole derivativesBAYER AG·Filed 2017·Granted Apr 20, 2021·9 cites·17 claims
- 0592US9320737B2Substituted imidazopyridazinesBAYER IP GMBH·Filed 2012·Granted Apr 26, 2016·27 cites·12 claims
- 0690US9730929B2Substituted aminoimidazopyridazinesEIS KNUT·Filed 2012·Granted Aug 15, 2017·25 cites·14 claims
- 0789US9993484B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2015·Granted Jun 12, 2018·4 cites·9 claims
- 0888US11142522B2Compounds, compositions and methods for cancer treatmentBROAD INST INC·Filed 2018·Granted Oct 12, 2021·4 cites·16 claims
- 0988US7750000B2Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicamentsBAYER SCHERING PHARMA AG·Filed 2006·Granted Jul 6, 2010·24 cites·2 claims
- 1086US7511059B2Thiazolidinones, their production and use as pharmaceutical agentsBAYER SCHERING PHARMA AG·Filed 2006·Granted Mar 31, 2009·14 cites·15 claims
- 1185US11529356B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2020·Granted Dec 20, 2022·1 cites·20 claims
- 1285US10772893B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2018·Granted Sep 15, 2020·2 cites·12 claims
- 1383US2024366620A1Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2024·Application pending·0 cites
- 1479US10966986B2Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2017·Granted Apr 6, 2021·1 cites·8 claims
- 1578US10266548B2Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2017·Granted Apr 23, 2019·2 cites·2 claims
- 1678US9643953B2Substituted benzylpyrazolesBAYER IP GMBH·Filed 2012·Granted May 9, 2017·5 cites·10 claims
- 1776US8653076B2Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticalsPRIEN OLAF·Filed 2007·Granted Feb 18, 2014·5 cites·17 claims
- 1875US9409889B2Amino-substituted imidazopyridazinesBayer Pharma AG·Filed 2013·Granted Aug 9, 2016·3 cites·9 claims
- 1974US12053476B2Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2021·Granted Aug 6, 2024·0 cites·6 claims
- 2074US11339157B14H-pyrrolo[3,2-c]pyridin-4-one derivativesBAYER AG·Filed 2018·Granted May 24, 2022·2 cites·19 claims
- 2174US9499547B2Amino-substituted imidazopyridazinesEIS KNUT·Filed 2012·Granted Nov 22, 2016·3 cites·16 claims
- 2272US9540392B2ThienopyrimidinesBayer Pharma AG·Filed 2013·Granted Jan 10, 2017·2 cites·10 claims
- 2364US10604532B2Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2019·Granted Mar 31, 2020·0 cites·6 claims
- 2462US2024109850A1Covalent PPARG inverse-agonistsBAYER AG·Filed 2023·Application pending·0 cites
- 2562US2024150277A1Covalent PPARG inverse-agonistsBAYER AG·Filed 2023·Application pending·0 cites
- 2654US9212140B2(5s,8s)-3-(4′-chlor-3′-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one (compound A) for treatmentLIU NINGSHU·Filed 2012·Granted Dec 15, 2015·0 cites·2 claims
- 2754US2010048891A1Metasubstituted thiazolidinones, their manufacture and use as a drugSCHULZE KLAUSE·Filed 2009·Application pending·0 cites
- 2853US2022235013A12-methyl-quinazolinesBayer Pharma AG·Filed 2018·Application pending·0 cites
- 2952US2014249133A1Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2012·Application pending·0 cites
- 3052US2011237592A1Substituted amido phenoxybenzamidesBAYER SCHERING PHARMA AG·Filed 2009·Application pending·0 cites
- 3151US2016046610A13-heteroaryl substituted indazolesBayer Pharma AG·Filed 2014·Application pending·0 cites
- 3251US2014135323A1Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticalsBAYER IP GMBH·Filed 2014·Application pending·0 cites
- 3348US8003787B2Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitorsBAYER SCHERING PHARMA AG·Filed 2008·Granted Aug 23, 2011·0 cites·21 claims
- 3448US2022227729A1Identification and use of kras inhibitorsBAYER AG·Filed 2020·Application pending·0 cites
- 3546US7598263B2Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising themBAYER SCHERING PHARMA AG·Filed 2007·Granted Oct 6, 2009·0 cites·17 claims
- 3646US2007015759A1Metasubstituted thiazolidinones, their manufacture and use as a drugSCHULZE VOLKER K·Filed 2005·Application pending·0 cites
- 3745US2007037862A1Thiazolidinones, their production and use as pharmaceutical agentsSIEMEISTER GERHARD·Filed 2004·Application pending·0 cites
- 3844US2008004268A1Inhibitors of soluble adenylate cyclaseNGUYEN DUY·Filed 2007·Application pending·0 cites
- 3943US9783543B2AminoimidazopyridazinesBayer Pharma AG·Filed 2013·Granted Oct 10, 2017·0 cites·8 claims
- 4043US9745304B2Amidoimidazopyridazines as MKNK-1 kinase inhibitorsBayer Pharma AG·Filed 2014·Granted Aug 29, 2017·0 cites·9 claims
- 4143US9296757B2Substituted benzothienopyrimidinesBayer Pharma AG·Filed 2013·Granted Mar 29, 2016·0 cites·9 claims
- 4243US7741333B2Quinazoline derivatives, their preparation, their use, and medicaments comprising themBAYER SCHERING PHARMA AG·Filed 2007·Granted Jun 22, 2010·0 cites·19 claims
- 4343US2022274979A12-methyl-aza-quinazolinesBayer Pharma AG·Filed 2019·Application pending·0 cites
- 4443US2006074084A1Inhibitors of soluble adenylate cyclaseNGUYEN DUY·Filed 2005·Application pending·0 cites
- 4543US2006079503A1Thiazolidinones and the use therof as polo-like kinase inhibitorsSCHERING AG·Filed 2003·Application pending·0 cites
- 4642US9777004B2Amino-substituted imidazopyridazinesBAYER IP GMBH·Filed 2013·Granted Oct 3, 2017·0 cites·9 claims
- 4741US9643974B2Amino-substituted imidazopyridazinesBAYER IP GMBH·Filed 2012·Granted May 9, 2017·0 cites·9 claims
- 4841US2008056987A1Quinoline derivatives, their preparation, their use, and medicaments comprising themPRIEN OLAF·Filed 2007·Application pending·0 cites
- 4940US10894784B2Heteroarylbenzimidazole compoundsBayer Pharma AG·Filed 2016·Granted Jan 19, 2021·0 cites·15 claims
- 5040US2018148418A1Amido-substituted cyclohexane derivativesBayer Pharma AG·Filed 2016·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Knut Eis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →